XOMA Royalty (XOMA) Competitors

$41.82 -0.16 (-0.38%)

Closing price 04:00 PM Eastern

Extended Trading

$41.86 +0.05 (+0.11%)

As of 04:10 PM Eastern

XOMA vs. XOMAO, INVA, NVAX, ZBIO, and LXRX

Should you buy XOMA Royalty stock or one of its competitors? MarketBeat compares XOMA Royalty with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with XOMA Royalty include XOMA (XOMAO), Innoviva (INVA), Novavax (NVAX), Zenas BioPharma (ZBIO), and Lexicon Pharmaceuticals (LXRX). These companies are all part of the "medical" sector.

How does XOMA Royalty compare to XOMA?

XOMA (NASDAQ:XOMAO) and XOMA Royalty (NASDAQ:XOMA) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, valuation, risk, institutional ownership, media sentiment, earnings, analyst recommendations and dividends.

XOMA Royalty has higher revenue and earnings than XOMA.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
XOMA	$7.65M	N/A	N/A	N/A	N/A
XOMA Royalty	$52.15M	10.06	$31.71M	$1.46	28.64

In the previous week, XOMA Royalty had 4 more articles in the media than XOMA. MarketBeat recorded 4 mentions for XOMA Royalty and 0 mentions for XOMA. XOMA Royalty's average media sentiment score of 0.69 beat XOMA's score of 0.00 indicating that XOMA Royalty is being referred to more favorably in the news media.

Company	Overall Sentiment
XOMA	Neutral
XOMA Royalty	Positive

95.9% of XOMA Royalty shares are held by institutional investors. 8.9% of XOMA Royalty shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

XOMA Royalty has a net margin of 53.46% compared to XOMA's net margin of 0.00%. XOMA Royalty's return on equity of 12.56% beat XOMA's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
XOMA	N/A	N/A	N/A
XOMA Royalty	53.46%	12.56%	4.11%

XOMA Royalty has a consensus target price of $53.75, suggesting a potential upside of 28.53%. Given XOMA Royalty's stronger consensus rating and higher possible upside, analysts clearly believe XOMA Royalty is more favorable than XOMA.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
XOMA	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
XOMA Royalty	0 Sell rating(s)	5 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.29

Summary

XOMA Royalty beats XOMA on 11 of the 11 factors compared between the two stocks.

How does XOMA Royalty compare to Innoviva?

XOMA Royalty (NASDAQ:XOMA) and Innoviva (NASDAQ:INVA) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, media sentiment, earnings, risk and valuation.

XOMA Royalty has a beta of 0.9, suggesting that its share price is 10% less volatile than the broader market. Comparatively, Innoviva has a beta of 0.38, suggesting that its share price is 62% less volatile than the broader market.

Innoviva has higher revenue and earnings than XOMA Royalty. Innoviva is trading at a lower price-to-earnings ratio than XOMA Royalty, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
XOMA Royalty	$52.15M	10.06	$31.71M	$1.46	28.64
Innoviva	$411.33M	3.98	$271.17M	$6.01	3.69

Innoviva has a net margin of 119.89% compared to XOMA Royalty's net margin of 53.46%. Innoviva's return on equity of 33.33% beat XOMA Royalty's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
XOMA Royalty	53.46%	12.56%	4.11%
Innoviva	119.89%	33.33%	22.67%

In the previous week, XOMA Royalty had 3 more articles in the media than Innoviva. MarketBeat recorded 4 mentions for XOMA Royalty and 1 mentions for Innoviva. XOMA Royalty's average media sentiment score of 0.69 beat Innoviva's score of -0.35 indicating that XOMA Royalty is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
XOMA Royalty	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Innoviva	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

95.9% of XOMA Royalty shares are owned by institutional investors. Comparatively, 99.1% of Innoviva shares are owned by institutional investors. 8.9% of XOMA Royalty shares are owned by company insiders. Comparatively, 2.0% of Innoviva shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

XOMA Royalty currently has a consensus target price of $53.75, indicating a potential upside of 28.53%. Innoviva has a consensus target price of $36.20, indicating a potential upside of 63.06%. Given Innoviva's stronger consensus rating and higher probable upside, analysts plainly believe Innoviva is more favorable than XOMA Royalty.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
XOMA Royalty	0 Sell rating(s)	5 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.29
Innoviva	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

Summary

Innoviva beats XOMA Royalty on 10 of the 16 factors compared between the two stocks.

How does XOMA Royalty compare to Novavax?

Novavax (NASDAQ:NVAX) and XOMA Royalty (NASDAQ:XOMA) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, risk, valuation, dividends, media sentiment, profitability, earnings and institutional ownership.

Novavax presently has a consensus price target of $12.13, indicating a potential upside of 35.02%. XOMA Royalty has a consensus price target of $53.75, indicating a potential upside of 28.53%. Given Novavax's higher possible upside, research analysts clearly believe Novavax is more favorable than XOMA Royalty.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Novavax	4 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.10
XOMA Royalty	0 Sell rating(s)	5 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.29

In the previous week, Novavax and Novavax both had 4 articles in the media. XOMA Royalty's average media sentiment score of 0.69 beat Novavax's score of 0.62 indicating that XOMA Royalty is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Novavax	1 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
XOMA Royalty	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Novavax has a beta of 2.37, indicating that its stock price is 137% more volatile than the broader market. Comparatively, XOMA Royalty has a beta of 0.9, indicating that its stock price is 10% less volatile than the broader market.

XOMA Royalty has a net margin of 53.46% compared to Novavax's net margin of -14.73%. XOMA Royalty's return on equity of 12.56% beat Novavax's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Novavax	-14.73%	-14.82%	1.23%
XOMA Royalty	53.46%	12.56%	4.11%

Novavax has higher revenue and earnings than XOMA Royalty. Novavax is trading at a lower price-to-earnings ratio than XOMA Royalty, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Novavax	$1.12B	1.31	$440.30M	-$0.58	N/A
XOMA Royalty	$52.15M	10.06	$31.71M	$1.46	28.64

53.0% of Novavax shares are held by institutional investors. Comparatively, 95.9% of XOMA Royalty shares are held by institutional investors. 1.0% of Novavax shares are held by insiders. Comparatively, 8.9% of XOMA Royalty shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

XOMA Royalty beats Novavax on 10 of the 15 factors compared between the two stocks.

How does XOMA Royalty compare to Zenas BioPharma?

Zenas BioPharma (NASDAQ:ZBIO) and XOMA Royalty (NASDAQ:XOMA) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, profitability, dividends, media sentiment, risk, institutional ownership, earnings and analyst recommendations.

In the previous week, Zenas BioPharma had 18 more articles in the media than XOMA Royalty. MarketBeat recorded 22 mentions for Zenas BioPharma and 4 mentions for XOMA Royalty. XOMA Royalty's average media sentiment score of 0.69 beat Zenas BioPharma's score of -0.06 indicating that XOMA Royalty is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zenas BioPharma	3 Very Positive mention(s)	0 Positive mention(s)	8 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
XOMA Royalty	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Zenas BioPharma currently has a consensus target price of $44.29, suggesting a potential upside of 123.21%. XOMA Royalty has a consensus target price of $53.75, suggesting a potential upside of 28.53%. Given Zenas BioPharma's stronger consensus rating and higher possible upside, analysts clearly believe Zenas BioPharma is more favorable than XOMA Royalty.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zenas BioPharma	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.56
XOMA Royalty	0 Sell rating(s)	5 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.29

Zenas BioPharma has a beta of -0.61, meaning that its share price is 161% less volatile than the broader market. Comparatively, XOMA Royalty has a beta of 0.9, meaning that its share price is 10% less volatile than the broader market.

95.9% of XOMA Royalty shares are owned by institutional investors. 22.0% of Zenas BioPharma shares are owned by company insiders. Comparatively, 8.9% of XOMA Royalty shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

XOMA Royalty has a net margin of 53.46% compared to Zenas BioPharma's net margin of 0.00%. XOMA Royalty's return on equity of 12.56% beat Zenas BioPharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zenas BioPharma	N/A	-99.99%	-58.06%
XOMA Royalty	53.46%	12.56%	4.11%

XOMA Royalty has higher revenue and earnings than Zenas BioPharma. Zenas BioPharma is trading at a lower price-to-earnings ratio than XOMA Royalty, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zenas BioPharma	$10M	125.25	-$377.74M	-$8.47	N/A
XOMA Royalty	$52.15M	10.06	$31.71M	$1.46	28.64

Summary

XOMA Royalty beats Zenas BioPharma on 10 of the 16 factors compared between the two stocks.

How does XOMA Royalty compare to Lexicon Pharmaceuticals?

Lexicon Pharmaceuticals (NASDAQ:LXRX) and XOMA Royalty (NASDAQ:XOMA) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, risk, profitability, earnings, institutional ownership, valuation, media sentiment and dividends.

74.7% of Lexicon Pharmaceuticals shares are owned by institutional investors. Comparatively, 95.9% of XOMA Royalty shares are owned by institutional investors. 14.0% of Lexicon Pharmaceuticals shares are owned by company insiders. Comparatively, 8.9% of XOMA Royalty shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

XOMA Royalty has higher revenue and earnings than Lexicon Pharmaceuticals. Lexicon Pharmaceuticals is trading at a lower price-to-earnings ratio than XOMA Royalty, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lexicon Pharmaceuticals	$49.80M	19.89	-$50.34M	-$0.07	N/A
XOMA Royalty	$52.15M	10.06	$31.71M	$1.46	28.64

In the previous week, XOMA Royalty had 1 more articles in the media than Lexicon Pharmaceuticals. MarketBeat recorded 4 mentions for XOMA Royalty and 3 mentions for Lexicon Pharmaceuticals. XOMA Royalty's average media sentiment score of 0.69 beat Lexicon Pharmaceuticals' score of 0.00 indicating that XOMA Royalty is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lexicon Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
XOMA Royalty	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Lexicon Pharmaceuticals has a beta of 0.97, meaning that its stock price is 3% less volatile than the broader market. Comparatively, XOMA Royalty has a beta of 0.9, meaning that its stock price is 10% less volatile than the broader market.

XOMA Royalty has a net margin of 53.46% compared to Lexicon Pharmaceuticals' net margin of -37.46%. XOMA Royalty's return on equity of 12.56% beat Lexicon Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lexicon Pharmaceuticals	-37.46%	-18.64%	-11.79%
XOMA Royalty	53.46%	12.56%	4.11%

Lexicon Pharmaceuticals currently has a consensus target price of $4.55, suggesting a potential upside of 104.04%. XOMA Royalty has a consensus target price of $53.75, suggesting a potential upside of 28.53%. Given Lexicon Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts clearly believe Lexicon Pharmaceuticals is more favorable than XOMA Royalty.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lexicon Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
XOMA Royalty	0 Sell rating(s)	5 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.29

Summary

XOMA Royalty beats Lexicon Pharmaceuticals on 10 of the 15 factors compared between the two stocks.

Get XOMA Royalty News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding XOMA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

XOMA vs. The Competition

Export

Metric	XOMA Royalty	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$524.42M	$3.36B	$6.34B	$12.28B
Dividend Yield	N/A	2.32%	2.80%	5.36%
P/E Ratio	26.64	19.02	20.92	25.48
Price / Sales	10.06	278.81	521.15	73.33
Price / Cash	72.86	125.35	43.18	55.00
Price / Book	5.65	6.90	9.98	7.01
Net Income	$31.71M	$24.23M	$3.55B	$335.16M
7 Day Performance	-0.43%	0.65%	0.40%	-0.30%
1 Month Performance	5.66%	-0.55%	-0.04%	1.14%
1 Year Performance	66.48%	63.42%	34.95%	34.69%

XOMA Royalty Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
XOMA XOMA Royalty	3.6715 of 5 stars	$41.82 -0.4%	$53.75 +28.5%	+57.8%	$524.42M	$52.15M	26.64	10	Positive News
XOMAO XOMA	N/A	$25.24 -0.3%	N/A	+0.3%	$0.00	$11.66M	N/A	10	Positive News
INVA Innoviva	3.6818 of 5 stars	$22.99 +2.1%	$36.20 +57.5%	+18.4%	$1.70B	$411.33M	3.83	100
NVAX Novavax	1.9568 of 5 stars	$9.62 +1.2%	$12.13 +26.1%	+20.7%	$1.59B	$1.12B	N/A	1,990	Gap Up
ZBIO Zenas BioPharma	3.2588 of 5 stars	$19.80 -2.9%	$44.14 +122.9%	+70.4%	$1.14B	$10M	N/A	N/A	Insider Trade Analyst Revision

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:XOMA) was last updated on 5/21/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

XOMA Royalty (XOMA) Competitors

XOMA vs. XOMAO, INVA, NVAX, ZBIO, and LXRX

How does XOMA Royalty compare to XOMA?

Summary

How does XOMA Royalty compare to Innoviva?

Summary

How does XOMA Royalty compare to Novavax?

Summary

How does XOMA Royalty compare to Zenas BioPharma?

Summary

How does XOMA Royalty compare to Lexicon Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

XOMA vs. The Competition

XOMA Royalty Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

XOMA Royalty (XOMA) Competitors

XOMA vs. XOMAO, INVA, NVAX, ZBIO, and LXRX

How does XOMA Royalty compare to XOMA?

Which has better valuation and earnings, XOMAO or XOMA?

Does the media favor XOMAO or XOMA?

Do institutionals and insiders have more ownership in XOMAO or XOMA?

Is XOMAO or XOMA more profitable?

Do analysts rate XOMAO or XOMA?

Summary

How does XOMA Royalty compare to Innoviva?

Which has more volatility & risk, XOMA or INVA?

Which has stronger earnings & valuation, XOMA or INVA?

Is XOMA or INVA more profitable?

Does the media prefer XOMA or INVA?

Do institutionals and insiders believe in XOMA or INVA?

Do analysts prefer XOMA or INVA?

Summary

How does XOMA Royalty compare to Novavax?

Do analysts recommend NVAX or XOMA?

Does the media prefer NVAX or XOMA?

Which has more risk & volatility, NVAX or XOMA?

Is NVAX or XOMA more profitable?

Which has stronger earnings & valuation, NVAX or XOMA?

Do institutionals & insiders have more ownership in NVAX or XOMA?

Summary

How does XOMA Royalty compare to Zenas BioPharma?

Does the media prefer ZBIO or XOMA?

Do analysts rate ZBIO or XOMA?

Which has more volatility & risk, ZBIO or XOMA?

Do institutionals and insiders have more ownership in ZBIO or XOMA?

Is ZBIO or XOMA more profitable?

Which has better earnings and valuation, ZBIO or XOMA?

Summary

How does XOMA Royalty compare to Lexicon Pharmaceuticals?

Do institutionals and insiders hold more shares of LXRX or XOMA?

Which has better earnings & valuation, LXRX or XOMA?

Does the media prefer LXRX or XOMA?

Which has more risk & volatility, LXRX or XOMA?

Is LXRX or XOMA more profitable?

Do analysts rate LXRX or XOMA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

XOMA vs. The Competition

XOMA Royalty Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools